Coherus Biosciences | CHRS - Current Liabilities


Coherus Biosciences reported $255.04M in Current Liabilities for its fiscal quarter ending in March of 2025.


Current Liabilities Change Date
AbbVie USD 36.4B 2.35B Mar/2025
Acadia Pharmaceuticals USD 330.02M 27.49M Jun/2025
ALKERMES USD 505.96M 62.23M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 225.22M Jun/2025
Amarin USD 162.41M 17.54M Mar/2025
Amgen USD 20.48B 2.53B Jun/2025
Baxter International USD 3.48B 3.03B Mar/2025
Biogen USD 3.18B 2.11B Jun/2025
BioMarin Pharmaceutical USD 684.25M 56.03M Jun/2025
Bristol-Myers Squibb USD 27.53B 3.46B Jun/2025
Eli Lilly USD 39.02B 8.95B Jun/2025
Fujifilm JPY 1.06T 64.7B Jun/2025
Gilead Sciences USD 11.19B 1.15B Jun/2025
Ironwood Pharmaceuticals USD 39.15M 10.24M Dec/2024
Merck USD 26.04B 863M Jun/2025
Myriad Genetics USD 151.1M 13M Mar/2025
Pacira USD 313.16M 1.57M Jun/2025
Perrigo USD 1.13B 52.3M Jun/2025
Pfizer USD 37.73B 1.27B Jun/2025
PTC Therapeutics USD 627.81M 32.42M Jun/2025
Regeneron Pharmaceuticals USD 3.67B 100.4M Jun/2025
Sarepta Therapeutics USD 919.95M 314.36M Jun/2025
Teva Pharmaceutical Industries USD 11.86B 704M Jun/2025
Vertex Pharmaceuticals USD 4.14B 355.2M Jun/2025
Xencor USD 96.08M 7.65M Jun/2025
Zoetis USD 3.37B 19M Jun/2025